NDC product
CLORAZEPATE DIPOTASSIUM
NDC 13107-319 · Aurolife Pharma LLC
Key facts
| Product NDC | 13107-319 |
|---|---|
| Proprietary name | CLORAZEPATE DIPOTASSIUM |
| Nonproprietary name | CLORAZEPATE DIPOTASSIUM |
| Substances | CLORAZEPATE DIPOTASSIUM |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Aurolife Pharma LLC |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA071858 |
| DEA schedule | CIV |
| Pharmacologic classes | Benzodiazepine [EPC], Benzodiazepines [CS] |
| Marketing start | Jul 17, 1987 |
| Marketing end | Feb 28, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory